Business Context and Reporting Period
This Form 6-K filing is submitted by Prana Biotechnology Limited (noted as Alterity Therapeutics Ltd in metadata) for the month of December 2012, with the report signed on December 12, 2012. The registrant is a foreign private issuer based in Parkville, Victoria, Australia.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a notification of a corporate governance event rather than a financial statement.
Material Changes
The primary material change disclosed in this filing is a Change in Director's Notice (Item 1, Appendix 3Y). No financial material changes are reported in this document.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the formal notification of the director change.
Investor Verification Checklist
- Verify the specific details of the director change referenced in Appendix 3Y.
- Confirm the current corporate name status, as the metadata lists "Alterity Therapeutics Ltd" while the filing header lists "Prana Biotechnology Limited."
- Review subsequent filings for financial data, as this 6-K contains no financial metrics.